Glenmark Pharmaceuticals, through a subsidiary, has entered into an exclusive license and collaboration agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody drug conjugate (ADC).
Under the agreement, Glenmark will get exclusive rights to develop and commercialise Trastuzumab Rezetecan in several countries, excluding Mainland China, USA, Europe, Japan and Russia among others. Glenmark will pay an upfront payment of $18 million.
Hengrui is eligible to receive regulatory and commercial milestone payments of up to $1.093 billion. Based on the net sales of Trastuzumab Rezetecan within the licensed territory, Glenmark will pay corresponding royalties to Hengrui.
Trastuzumab Rezetecan is Hengrui’s HER2-targeted ADC. In May 2025, it was approved in China for the treatment of adult patients with HER2 (ERBB2) activating mutations in unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.
In September, the new indication for Trastuzumab Rezetecan in breast cancer was accepted by China’s NMPA for review. Trastuzumab Rezetecan has been included in the NMPA’s Breakthrough Therapy Designation list for nine indications, covering NSCLC, breast cancer, gastric or gastroesophageal junction adenocarcinoma, colorectal cancer, biliary tract cancer, and gynecologic malignancies, Glenmark said in a release on Wednesday.
Published – September 24, 2025 09:14 pm IST